Epidemiology of Intravenous Immune Globulin in Septic Shock
link.springer.comIntravenous immune globulin is used infrequently across the US in patients with septic shock. Regimens of IVIG in septic shock may be less intensive than those associated with a survival benefit in meta-analyses. Observed infrequent use supports apparent clinical equipoise, perhaps secondary to limitations of the primary literature.
This is a retrospective database study of adult patients with septic shock admitted to US hospitals in the Premier Healthcare Database (from July 2010 to June 2013).
A clinical trial evaluating the role of IVIG in septic shock is needed.
Intravenous immune globulin was administered to 0.3% (n = 685) of patients with septic shock; with a median [interquartile range (IQR)] dose of 1 [0.5–1.8] g·kg-1 for a median [IQR] of 1 [1–2] day.